We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Product Availability Update

Promega Manufacturing and Delivery Systems continue to be fully operational during the COVID-19 outbreak. Our teams are in regular contact with suppliers and distributors worldwide and are taking all steps necessary to address both demands for diagnostic tools and reliable delivery of all products as quickly as possible. Learn more

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Citations Search

Sort By:

PLos ONE 9, e104566. Comparison of Pre-Analytical FFPE Sample Preparation Methods and Their Impact on Massively Parallel Sequencing in Routine Diagnostics 2014

Heydt, C., Fassunke, J., Künstlinger, H., Ihle, M.A., König, K., Heukamp, L.C., Schidhaus, H-U., Odenthal, M., Büttner, R. and Merkelbach-Bruse, S.

Notes: The authors of this study set out to compare five automated systems for purification of DNA from FFPE tissue samples and five DNA quantification methods to determine the systems and methods most favorable to successful downstream massively parallel sequencing (next generation sequencing) analysis. Tissues were processed using commercially available DNA purification kits available for each platform. The authors concluded that the DNA extracted using the Maxwell® 16 systems and platform was of the highest quality in this study and gave the best results in downstream applications. (4512)

Expand Full Notes »

19, 1469–1472. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. 2014

Vaishnavi, A., Capelletti, M., Le, A.T., Kako, S., Butaney, M., Ercan, D., Mahale, S., Davies, K.D., Aisner, D.L., Pilling, A.B., Berge, E.M., Kim, J., Sasaki, H., Park, S., Kryukov, G., Garraway, L.A., Hammerman, P.S., Haas, J., Andrews, S.W., Lipson, D., Stephens, P.J., Miller, V.A., Varella-Garcia, M., Jänne, P.A. and Doebele, R.C.

Notes: The authors extracted DNA from FFPE or frozen lung cancer samples using the Maxwell® 16 Instrument and the Maxwell® 16 FFPE Plus LEV DNA Kit. Target enrichment was performed, followed by NGS on an Illumina HiSeq 2000 Instrument. (4908)

Expand Full Notes »

Human Pathology 45, 701–708. Molecular characterization of gallbladder cancer using somatic mutation profiling. 2013

Javle, M., Rashid, A., Churi, C., Kar, S., Zuo, M., Eterovic, A.K., Nogueras-Gonzalez, G.M., Janku, F., Shroff, R.T., Aloia, T.A., Vauthey, J.N., Curley, S., Mills, G. and Roa, I.

Notes: The authors extracted DNA from gallbladder cancer FFPE samples using the Maxwell® 16 Instrument and the FFPE Plus DNA Kit. The also performed target enrichment followed by NGS on an Illumina HiSeq 2000 Instrument. (4907)

Expand Full Notes »

Eur Urol. 63, 920–926. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. 2013

Beltran, H., Yelensky, R., Frampton, G.M., Park, K., Downing, S.R., MacDonald, T.Y., Jarosz, M., Lipson, D., Tagawa, S.T., Nanus, D.M., Stephens, P.J., Mosquera, J.M., Cronin, M.T. and Rubin, M.A.

Notes: The authors extracted DNA from FFPE samples using the Maxwell® 16 Instrument and an unidentified Maxwell® FFPE DNA Kit. Purified DNA was subjected to NGS on an Illumina HiSeq 2000 Instrument. (4906)

Expand Full Notes »